New MS drug trial targets chinese patients
NCT ID NCT07483450
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study tests the drug ocrelizumab in 60 Chinese adults with two forms of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see if it reduces relapses and controls disease activity. Participants receive ocrelizumab infusions, and researchers track relapses, brain scans, and B-cell levels over 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ocrelizumab (OCREVUS)
- What this could lead to
- If successful, this could confirm that ocrelizumab works well for Chinese MS patients, offering a treatment option to reduce relapses and slow disability progression.
- What could go wrong
- This is a small, open-label study with no placebo group, so results may not be definitive. Ocrelizumab can increase infection risk and infusion reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
1st Affiliated Hospital of Shanxi Medical University
Taiyuan, 030000, China
-
Beijing Hospital of Ministry of Health
Beijing, 100730, China
-
Inner Mongolia Autonomous Region People's Hospital
Hohhot, 010011, China
-
Lanzhou University Second Hospital
Lanzhou, 730030, China
-
Peking Union Medical College Hospital
Beijing, 100032, China
-
Peking University First Hospital
Beijing, 100034, China
-
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, 310003, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330209, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, 510080, China
-
The First Affiliated Hospital, Chongqing Medical University
Chongqing, 400016, China
-
The First Hospital of China Medical University
Shenyang, DUMMY_VALUE, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, 050000, China
-
The Third Affiliated Hospital of Sun Yat-Sen University
Guangzhou, 510630, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430030, China
-
West China Hospital of Sichuan University
Chengdu, 610041, China
-
Xiangya Hospital Central South University
Changsha, 410008, China
-
Xinjiang People Hospital
Ürümqi, 830000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.